{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-006281","form_type":"8-K","ticker":"SBFM","cik":"0001402328","company_name":"Sunshine Biopharma Inc.","filed_at":"2024-09-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.922331+00:00","generated_at":"2026-05-31T05:36:31.657118+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sunshine Biopharma regains Nasdaq bid-price compliance; faces 1-year monitoring with strict delisting risk","bullets":["Received Nasdaq letter confirming compliance with Bid Price Rule (Listing Rule 5550(a)(2)).","Subject to Mandatory Panel Monitor for one year from September 9, 2024.","If non-compliant during monitoring, no cure period allowed; Nasdaq will issue Delist Determination Letter.","Company may request a new hearing if delist determination is issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-006281","json":"https://secwatch.observer/filing/0001683168-24-006281.json","markdown":"https://secwatch.observer/filing/0001683168-24-006281.md","text":"https://secwatch.observer/filing/0001683168-24-006281.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824006281/0001683168-24-006281-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1402328/000168316824006281/sunshine_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:36:31.657118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}